AI Therapeutics Logo.jpg
AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
August 31, 2023 10:38 ET | AI Therapeutics, Inc.
GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology
November 14, 2017 07:00 ET | Neuronascent, Inc.
CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. (, a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today...